Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Corvus Pharmaceuticals, Inc. (CRVS)
USD15.06
+0.09 (+0.60%)
US NASDAQ Healthcare Biotechnology
Address
863 Mitten Road 94010
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Richard A. Miller
Website
corvuspharma.com
IPO
2016-03-23
CIK 1626971 ISIN US2210151005
Description
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD15.06
+0.09 (+0.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.82
Float Shares
64.11M
Free Float %
76.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.57% | -3.25% | +1.67% | -28.69% | +91.97% | +89.48% | +355.94% | +1,022.31% | +401.37% | +17.09% | +2.39% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
15.06
Low
27.00
+79.3%
Consensus
33.17
+120.3%
Median
31.00
+105.8%
High
42.00
+178.9%
DCF (Unlevered)
0.02
-99.9%
DCF (Levered)
0.05
-99.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
40.00
+165.6%
|
| Last Quarter | 1 |
40.00
+165.6%
|
| Last Year | 10 |
25.90
+72.0%
|
| All Time | 13 |
22.38
+48.6%
|
Quality scores
Altman Z-Score
56.92
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+48.0% ★ Q1'26: -15.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-796.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+30.8% Q1'26: +19.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 600.0K (-100.0%)
|
1.18M
662.4K – 1.71M
+96.7% YoY
|
8.41M
7.29M – 9.52M
+612.3% YoY
|
44.11M
24.76M – 63.99M
+424.7% YoY
|
102.52M
57.55M – 148.75M
+132.4% YoY
|
183.63M
103.08M – 266.43M
+79.1% YoY
|
| EBITDA |
-27.46M
|
-42.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-27.55M
|
-42.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-62.29M
est: -56.51M (-10.2%)
|
-15.28M
est: -18.39M (+16.9%)
|
-59.99M
-60.42M – -45.12M
-226.3% YoY
|
-57.15M
-63.50M – -50.80M
+4.7% YoY
|
-49.53M
-92.05M – 4.22M
+13.3% YoY
|
-4.78M
-7.59M – -2.06M
+90.3% YoY
|
45.45M
19.53M – 72.10M
+1,050.0% YoY
|
| SGA |
8.16M
|
9.25M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.02
est: -0.92 (-10.7%)
|
-0.19
est: -0.25 (+22.4%)
|
-0.63
-0.76 – -0.57
-158.4% YoY
|
-0.72
-0.80 – -0.64
-13.2% YoY
|
-0.55
-1.15 – 0.05
+23.7% YoY
|
-0.06
-0.10 – -0.03
+89.0% YoY
|
0.57
0.24 – 0.90
+1,050.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
36
Total invested
34.54M
Insider transactions (90d)
1
Beneficial owners (>5%)
38
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | 17.05M | 9.90% | — | 17.05M | — | — | PN | Delaware | 2024-05-09 | ↗ |
| 2 | Point72 Capital Advisors, Inc. | 17.05M | 9.90% | — | 17.05M | — | — | CO | Delaware | 2024-05-09 | ↗ |
| 3 | Steven A. Cohen | 17.05M | 9.90% | — | 17.05M | — | — | IN | Delaware | 2024-05-09 | ↗ |
| 4 | Israel A. Englander | 2.92M | 6.30% | — | 2.92M | — | 2.92M | IN | — | 2022-01-18 | ↗ |
| 5 | Millennium Group Management LLC | 2.92M | 6.30% | — | 2.92M | — | 2.92M | OO | — | 2022-01-18 | ↗ |
| 6 | Millennium Management LLC | 2.92M | 6.30% | — | 2.92M | — | 2.92M | OO | — | 2022-01-18 | ↗ |
| 7 | Richard A. Miller | 2.61M | 5.45% | 1.32M | 1.29M | 1.32M | 1.29M | IN | United States of America | 2022-02-14 | ↗ |
| 8 | Robert Pohly | 2.50M | 5.10% | — | 2.50M | — | 2.50M | HC, IN | Delaware | 2024-02-14 | ↗ |
| 9 | Samlyn Capital, LLC | 2.50M | 5.10% | — | 2.50M | — | 2.50M | IA, OO | Delaware | 2024-02-14 | ↗ |
| 10 | Samlyn, LP | 2.50M | 5.10% | — | 2.50M | — | 2.50M | PN | Delaware | 2024-02-14 | ↗ |
| 11 | CHI Advisors LLC | 2.38M | 5.12% | 2.38M | — | 2.38M | — | IA | Delaware | 2023-02-13 | ↗ |
| 12 | Integrated Core Strategies (US) LLC | 2.24M | 4.80% | — | 2.24M | — | 2.24M | OO | — | 2022-01-18 | ↗ |
| 13 | BVF Inc. | 1.37M | 3.00% | — | — | — | 1.37M | CO | — | 2022-02-14 | ↗ |
| 14 | BVF Partners L.P. | 1.37M | 3.00% | — | — | — | 1.37M | IA, PN | — | 2022-02-14 | ↗ |
| 15 | Mark N. Lampert | 1.37M | 3.00% | — | — | — | 1.37M | IN | — | 2022-02-14 | ↗ |
| 16 | Sandra J. Horning | 1.29M | 2.77% | — | 1.29M | — | 1.29M | IN | United States of America | 2022-02-14 | ↗ |
| 17 | of the Miller-Horning Family Trust u/a/d January 25, 1985 | 1.29M | 2.77% | 1.29M | — | 1.29M | — | OO | United States of America | 2022-02-14 | ↗ |
| 18 | BVF GP HOLDINGS LLC | 1.26M | 2.70% | — | — | — | 1.26M | OO | — | 2022-02-14 | ↗ |
| 19 | BVF I GP LLC | 730.5K | 1.60% | — | — | — | 730.5K | OO | — | 2022-02-14 | ↗ |
| 20 | Biotechnology Value Fund, L.P. | 730.5K | 1.60% | — | — | — | 730.5K | PN | — | 2022-02-14 | ↗ |
| 21 | Millennium International Management LP | 684.5K | 1.50% | — | 684.5K | — | 684.5K | PN | — | 2022-01-18 | ↗ |
| 22 | Integrated Assets II LLC | 684.4K | 1.50% | — | 684.4K | — | 684.4K | OO | — | 2022-01-18 | ↗ |
| 23 | BVF II GP LLC | 533.3K | 1.20% | — | — | — | 533.3K | OO | — | 2022-02-14 | ↗ |
| 24 | Biotechnology Value Fund II, L.P. | 533.3K | 1.20% | — | — | — | 533.3K | PN | — | 2022-02-14 | ↗ |
| 25 | Koh, Bong | 250.0K | 0.50% | — | 250.0K | — | 250.0K | IN | United States | 2022-02-14 | ↗ |
| 26 | Shah, Nimish | 250.0K | 0.50% | — | 250.0K | — | 250.0K | IN | United States | 2022-02-14 | ↗ |
| 27 | VHCP Co-Investment Holdings II, LLC | 250.0K | 0.50% | — | 250.0K | — | 250.0K | OO | Delaware | 2022-02-14 | ↗ |
| 28 | VHCP Co-Investment Holdings III, LLC | 250.0K | 0.50% | — | 250.0K | — | 250.0K | OO | Delaware | 2022-02-14 | ↗ |
| 29 | VHCP Management EG, LLC | 250.0K | 0.50% | — | 250.0K | — | 250.0K | OO | Delaware | 2022-02-14 | ↗ |
| 30 | VHCP Management II, LLC | 250.0K | 0.50% | — | 250.0K | — | 250.0K | OO | Delaware | 2022-02-14 | ↗ |
| 31 | VHCP Management III, LLC | 250.0K | 0.50% | — | 250.0K | — | 250.0K | OO | Delaware | 2022-02-14 | ↗ |
| 32 | Venrock Healthcare Capital Partners EG, L.P. | 250.0K | 0.50% | — | 250.0K | — | 250.0K | PN | Delaware | 2022-02-14 | ↗ |
| 33 | Venrock Healthcare Capital Partners II, L.P. | 250.0K | 0.50% | — | 250.0K | — | 250.0K | PN | Delaware | 2022-02-14 | ↗ |
| 34 | Venrock Healthcare Capital Partners III, L.P. | 250.0K | 0.50% | — | 250.0K | — | 250.0K | PN | Delaware | 2022-02-14 | ↗ |
| 35 | BVF Partners OS Ltd. | 82.0K | 1.00% | — | — | — | 82.0K | CO | — | 2022-02-14 | ↗ |
| 36 | Biotechnology Value Trading Fund OS LP | 82.0K | 1.00% | — | — | — | 82.0K | PN | — | 2022-02-14 | ↗ |
| 37 | Integrated Assets, Ltd. | 2.2K | 0.00% | — | 2.2K | — | 2.2K | CO | — | 2021-10-22 | ↗ |
| 38 | ICS Opportunities, Ltd. | 89.00 | 0.00% | — | 89.00 | — | 89.00 | CO | — | 2022-01-18 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
36
-97 vs prev Q
New positions
11
Closed positions
100
Increased
25
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 7.17M +— (+0.0%) | 55.17M +2.4M (+4.5%) | 8.65% -0.563 pp | 1.13% -0.114 pp | USD11.17 -31.1% | 40 qtrs — |
| 2 | BLACKROCK, INC. | 5.06M +345.9K (+7.3%) | 38.93M +4.2M (+12.2%) | 6.10% +0.048 pp | 0.00% +0.000 pp | USD4.84 +59.1% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 3.87M +401.6K (+11.6%) | 29.83M +4.2M (+16.6%) | 4.68% +0.212 pp | 0.00% +0.000 pp | USD4.97 +54.9% | 39 qtrs — |
| 4 | MORGAN STANLEY | 3.57M +3.0M (+478.1%) | 27.47M +22.9M (+503.9%) | 4.31% +3.514 pp | 0.00% +0.001 pp | USD6.87 +12.1% | 40 qtrs — |
| 5 | ADAMS STREET PARTNERS LLC | 3.28M +— (+0.0%) | 25.22M +1.1M (+4.5%) | 3.95% -0.257 pp | 9.56% -6.199 pp | USD13.97 -44.9% | 40 qtrs — |
| 6 | POINT72 ASSET MANAGEMENT, L.P. | 2.88M -3.6M (-55.5%) | 22.14M -25.4M (-53.5%) | 3.47% -4.828 pp | 0.02% -0.055 pp | USD3.15 +144.4% | 7 qtrs — |
| 7 | STATE STREET CORP | 2.79M +1.8M (+177.1%) | 21.47M +14.1M (+189.5%) | 3.37% +2.072 pp | 0.00% +0.001 pp | USD6.77 +13.7% | 19 qtrs — |
| 8 | BIOIMPACT CAPITAL LLC | 2.74M +2.7M (+100.0%) | 21.13M +21.1M (+100.0%) | 3.31% +3.312 pp | 2.42% +2.417 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 9 | VIVO CAPITAL, LLC | 2.23M +— (+0.0%) | 17.21M +737.4K (+4.5%) | 2.70% -0.176 pp | 1.11% -0.213 pp | USD5.30 +45.3% | 6 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.47M +16.5K (+1.1%) | 11.35M +608.2K (+5.7%) | 1.78% -0.095 pp | 0.00% +0.000 pp | USD4.38 +75.8% | 38 qtrs — |
| 11 | FORESITE CAPITAL MANAGEMENT VI LLC | 1.38M -350.0K (-20.2%) | 10.64M -2.1M (-16.6%) | 1.67% -0.559 pp | 3.21% -1.714 pp | USD5.23 +47.2% | 5 qtrs — |
| 12 | DCF ADVISERS, LLC | 729.0K +729.0K (+100.0%) | 5.61M +5.6M (+100.0%) | 0.88% +0.880 pp | 1.51% +1.506 pp | USD7.70 +0.0% | 4 qtrs — |
| 13 | PERCEPTIVE ADVISORS LLC | 692.4K -746.2K (-51.9%) | 5.33M -5.3M (-49.7%) | 0.84% -1.014 pp | 0.10% -0.211 pp | USD4.00 +92.5% | 3 qtrs — |
| 14 | MILLENNIUM MANAGEMENT LLC | 688.8K +688.8K (+100.0%) | 5.30M +5.3M (+100.0%) | 0.83% +0.832 pp | 0.00% +0.002 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 15 | GOLDMAN SACHS GROUP INC | 553.3K +107.7K (+24.2%) | 4.26M +976.0K (+29.7%) | 0.67% +0.095 pp | 0.00% +0.000 pp | USD6.80 +13.2% | 6 qtrs — |
| 16 | LOGOS GLOBAL MANAGEMENT LP | 500.0K +500.0K (+100.0%) | 3.85M +3.9M (+100.0%) | 0.60% +0.604 pp | 0.23% +0.233 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 17 | ADAR1 CAPITAL MANAGEMENT, LLC | 465.9K +465.9K (+100.0%) | 3.59M +3.6M (+100.0%) | 0.56% +0.562 pp | 0.26% +0.264 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 18 | RTW INVESTMENTS, LP | 447.6K -2.2M (-83.3%) | 3.45M -16.3M (-82.5%) | 0.54% -2.905 pp | 0.03% -0.209 pp | USD5.35 +43.9% | 5 qtrs — |
| 19 | NORTHERN TRUST CORP | 429.8K -36.7K (-7.9%) | 3.31M -128.8K (-3.7%) | 0.52% -0.081 pp | 0.00% +0.000 pp | USD4.72 +63.1% | 39 qtrs — |
| 20 | SPHERA FUNDS MANAGEMENT LTD. | 407.7K +— (+0.0%) | 3.14M +134.5K (+4.5%) | 0.49% -0.032 pp | 0.61% -0.027 pp | USD6.46 +19.2% | 5 qtrs — |
| 21 | BARCLAYS PLC | 394.8K +394.8K (+39,476,500.0%) | 3.04M +3.0M (+60,793,860.0%) | 0.48% +0.477 pp | 0.00% +0.001 pp | USD7.70 +0.0% | 10 qtrs — |
| 22 | JANE STREET GROUP, LLC | 378.3K +310.2K (+455.8%) | 2.91M +2.4M (+480.7%) | 0.46% +0.369 pp | 0.00% +0.000 pp | USD7.55 +2.0% | 6 qtrs — |
| 23 | WELLINGTON MANAGEMENT GROUP LLP | 314.7K +134.5K (+74.7%) | 2.42M +1.1M (+82.5%) | 0.38% +0.148 pp | 0.00% +0.000 pp | USD6.15 +25.2% | 4 qtrs — |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 260.2K +216.1K (+490.0%) | 2.00M +1.7M (+516.4%) | 0.31% +0.257 pp | 0.00% +0.000 pp | USD7.39 +4.2% | 11 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 236.5K +84.5K (+55.6%) | 1.82M +701.0K (+62.6%) | 0.29% +0.090 pp | 0.00% +0.000 pp | USD6.14 +25.4% | 13 qtrs — |
| 26 | MARSHALL WACE, LLP | 216.2K +216.2K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.26% +0.261 pp | 0.00% +0.002 pp | USD7.70 +0.0% | 7 qtrs — |
| 27 | UBS GROUP AG | 212.0K +49.9K (+30.8%) | 1.63M +438.0K (+36.7%) | 0.26% +0.048 pp | 0.00% +0.000 pp | USD6.09 +26.4% | 24 qtrs — |
| 28 | CITADEL ADVISORS LLC | 208.2K +165.4K (+386.8%) | 1.60M +1.3M (+408.6%) | 0.25% +0.196 pp | 0.00% +0.000 pp | USD7.63 +0.9% | 10 qtrs — |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 171.2K -6.6K (-3.7%) | 1.32M +7.7K (+0.6%) | 0.21% -0.022 pp | 0.00% +0.000 pp | USD4.26 +80.8% | 11 qtrs — |
| 30 | EMPIRICAL FINANCIAL SERVICES, LLC D.B.A. EMPIRICAL WEALTH MANAGEMENT | 167.4K -1.8K (-1.1%) | 1.29M +42.0K (+3.4%) | 0.20% -0.016 pp | 0.02% -0.002 pp | USD4.02 +91.5% | 3 qtrs — |
| 31 | FRED ALGER MANAGEMENT, LLC | 144.4K +144.4K (+100.0%) | 1.11M +1.1M (+100.0%) | 0.17% +0.174 pp | 0.00% +0.004 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 32 | TWO SIGMA INVESTMENTS, LP | 143.6K -59.8K (-29.4%) | 1.11M -393.1K (-26.2%) | 0.17% -0.088 pp | 0.00% -0.001 pp | USD3.18 +142.1% | 20 qtrs — |
| 33 | TOWERVIEW LLC | 140.0K -30.0K (-17.6%) | 1.08M -174.9K (-14.0%) | 0.17% -0.050 pp | 0.78% -0.130 pp | USD2.81 +174.0% | 11 qtrs — |
| 34 | BANK OF NEW YORK MELLON CORP | 131.6K +5.1K (+4.0%) | 1.01M +81.0K (+8.7%) | 0.16% -0.004 pp | 0.00% +0.000 pp | USD4.55 +69.2% | 3 qtrs — |
| 35 | RAYMOND JAMES FINANCIAL INC | 121.2K -3.3K (-2.7%) | 932.9K +15.4K (+1.7%) | 0.15% -0.014 pp | 0.00% +0.000 pp | USD5.17 +48.9% | 5 qtrs — |
| 36 | QUBE RESEARCH & TECHNOLOGIES LTD | 114.5K +114.5K (+100.0%) | 881.7K +881.7K (+100.0%) | 0.14% +0.138 pp | 0.00% +0.001 pp | USD7.70 +0.0% | 8 qtrs — |
| 37 | CAPTION MANAGEMENT, LLC | 105.9K +105.9K (+100.0%) | 815.4K +815.4K (+100.0%) | 0.13% +0.128 pp | 0.01% +0.006 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 38 | SQUAREPOINT OPS LLC | 104.8K +104.8K (+100.0%) | 807.1K +807.1K (+100.0%) | 0.13% +0.127 pp | 0.00% +0.001 pp | USD7.70 +0.0% | 6 qtrs — |
| 39 | RAFFERTY ASSET MANAGEMENT, LLC | 99.7K +99.7K (+100.0%) | 767.9K +767.9K (+100.0%) | 0.12% +0.120 pp | 0.00% +0.003 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 40 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 86.7K +86.7K (+100.0%) | 667.7K +667.7K (+100.0%) | 0.10% +0.105 pp | 0.01% +0.005 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 41 | NEOS INVESTMENT MANAGEMENT LLC | 80.9K +21.7K (+36.6%) | 622.9K +186.6K (+42.8%) | 0.10% +0.022 pp | 0.00% +0.000 pp | USD7.46 +3.2% | 2 qtrs — |
| 42 | TEMA ETFS LLC | 79.7K +20.5K (+34.6%) | 613.7K +177.4K (+40.6%) | 0.10% +0.020 pp | 0.05% +0.011 pp | USD7.45 +3.4% | 2 qtrs — |
| 43 | RHUMBLINE ADVISERS | 70.7K -11.9K (-14.4%) | 544.6K -64.1K (-10.5%) | 0.09% -0.021 pp | 0.00% +0.000 pp | USD4.25 +81.2% | 11 qtrs — |
| 44 | NUVEEN, LLC | 68.1K +— (+0.0%) | 524.1K +22.5K (+4.5%) | 0.08% -0.005 pp | 0.00% +0.000 pp | USD4.00 +92.5% | 3 qtrs — |
| 45 | ADVISOR GROUP HOLDINGS, INC. | 68.0K +1.0 (+0.0%) | 523.5K +133.3K (+34.1%) | 0.08% -0.005 pp | 0.00% +0.000 pp | USD5.32 +44.7% | 24 qtrs — |
| 46 | D. E. SHAW & CO., INC. | 64.9K +39.3K (+153.8%) | 499.8K +311.4K (+165.2%) | 0.08% +0.046 pp | 0.00% +0.000 pp | USD7.57 +1.7% | 2 qtrs — |
| 47 | JACKSON SQUARE CAPITAL, LLC | 63.8K +— (+0.0%) | 491.1K +21.0K (+4.5%) | 0.08% -0.005 pp | 0.10% -0.005 pp | USD1.64 +369.5% | 16 qtrs — |
| 48 | WELLS FARGO & COMPANY/MN | 62.6K +26.2K (+72.1%) | 482.2K +214.0K (+79.8%) | 0.08% +0.029 pp | 0.00% +0.000 pp | USD6.03 +27.7% | 5 qtrs — |
| 49 | ALPS ADVISORS INC | 61.3K +61.3K (+100.0%) | 472.1K +472.1K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.003 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 50 | HSBC HOLDINGS PLC | 59.3K -23.1K (-28.1%) | 451.0K -135.6K (-23.1%) | 0.07% -0.034 pp | 0.00% 0.000 pp | USD4.00 +92.5% | 3 qtrs — |
| 51 | DEUTSCHE BANK AG\ | 56.0K +2.4K (+4.5%) | 431.5K +36.2K (+9.2%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD4.74 +62.4% | 3 qtrs — |
| 52 | DIADEMA PARTNERS LP | 53.1K +3.1K (+6.2%) | 408.9K +40.4K (+11.0%) | 0.06% 0.000 pp | 0.07% -0.024 pp | USD7.39 +4.2% | 2 qtrs — |
| 53 | HIKARI POWER LTD | 50.0K +— (+0.0%) | 385.0K +17.0K (+4.6%) | 0.06% -0.004 pp | 0.03% +0.001 pp | USD2.90 +165.5% | 30 qtrs — |
| 54 | ANCORA ADVISORS, LLC | 47.7K +377.0 (+0.8%) | 367.0K +18.5K (+5.3%) | 0.06% -0.003 pp | 0.01% +0.001 pp | USD5.36 +43.7% | 6 qtrs — |
| 55 | INVESCO LTD. | 43.6K +4.9K (+12.7%) | 335.6K +50.6K (+17.7%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD4.42 +74.2% | 3 qtrs — |
| 56 | CREATIVE PLANNING | 39.2K +13.9K (+54.9%) | 301.7K +115.2K (+61.8%) | 0.05% +0.015 pp | 0.00% +0.000 pp | USD7.49 +2.8% | 2 qtrs — |
| 57 | PROFUND ADVISORS LLC | 37.1K +37.1K (+100.0%) | 285.4K +285.4K (+100.0%) | 0.04% +0.045 pp | 0.01% +0.009 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 58 | INTECH INVESTMENT MANAGEMENT LLC | 36.0K +9.8K (+37.5%) | 277.0K +84.2K (+43.7%) | 0.04% +0.010 pp | 0.00% +0.001 pp | USD5.05 +52.5% | 3 qtrs — |
| 59 | QUEST PARTNERS LLC | 36.0K +36.0K (+100.0%) | 277.0K +277.0K (+100.0%) | 0.04% +0.043 pp | 0.02% +0.016 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 60 | PRICE T ROWE ASSOCIATES INC /MD/ | 34.1K +1.7K (+5.2%) | 263.0K +24.0K (+10.0%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD4.79 +60.8% | 3 qtrs — |
| 61 | AVITY INVESTMENT MANAGEMENT INC. | 32.7K +— (+0.0%) | 251.6K +10.8K (+4.5%) | 0.04% -0.003 pp | 0.02% +0.001 pp | USD3.74 +105.9% | 10 qtrs — |
| 62 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 32.4K +4.9K (+17.7%) | 248.3K +45.5K (+22.4%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD4.56 +68.9% | 3 qtrs — |
| 63 | VIRTUS INVESTMENT ADVISERS, INC. | 31.8K +4.9K (+18.4%) | 244.7K +46.9K (+23.7%) | 0.04% +0.004 pp | 0.07% +0.010 pp | USD4.55 +69.2% | 4 qtrs — |
| 64 | METLIFE INVESTMENT MANAGEMENT, LLC | 30.8K -2.8K (-8.4%) | 237.0K -10.6K (-4.3%) | 0.04% -0.006 pp | 0.00% +0.000 pp | USD4.15 +85.5% | 3 qtrs — |
| 65 | JPMORGAN CHASE & CO | 30.7K -1.6K (-4.9%) | 236.0K -1.5K (-0.6%) | 0.04% -0.004 pp | 0.00% +0.000 pp | USD4.28 +79.9% | 17 qtrs — |
| 66 | ARGENT ADVISORS, INC. | 30.0K +— (+0.0%) | 231.0K +9.9K (+4.5%) | 0.04% -0.002 pp | 0.06% -0.001 pp | USD4.00 +92.5% | 3 qtrs — |
| 67 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 28.1K +28.1K (+100.0%) | 216.5K +216.5K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.001 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 68 | VOYA INVESTMENT MANAGEMENT LLC | 27.7K +27.7K (+100.0%) | 213.0K +213.0K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD7.70 +0.0% | 3 qtrs — |
| 69 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 26.7K -40.0K (-60.0%) | 205.6K -286.0K (-58.2%) | 0.03% -0.054 pp | 0.00% -0.006 pp | USD3.26 +136.2% | 25 qtrs — |
| 70 | GROUP ONE TRADING, L.P. | 26.7K +26.7K (+100.0%) | 205.3K +205.3K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 71 | PALUMBO WEALTH MANAGEMENT LLC | 26.3K +2.6K (+11.2%) | 202.2K +28.1K (+16.2%) | 0.03% +0.001 pp | 0.05% -0.006 pp | USD7.40 +4.1% | 2 qtrs — |
| 72 | BALYASNY ASSET MANAGEMENT L.P. | 25.0K -541.0 (-2.1%) | 192.7K +4.3K (+2.3%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD7.37 +4.5% | 5 qtrs — |
| 73 | DRW SECURITIES, LLC | 23.4K +23.4K (+100.0%) | 180.1K +180.1K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.005 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 74 | THREE BRIDGE WEALTH ADVISORS, LLC | 22.4K +— (+0.0%) | 172.3K +7.4K (+4.5%) | 0.03% -0.002 pp | 0.05% +0.003 pp | USD5.35 +43.9% | 5 qtrs — |
| 75 | VERITION FUND MANAGEMENT LLC | 21.4K +21.4K (+100.0%) | 164.6K +164.6K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.001 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 76 | COMMERCE BANK | 20.0K +— (+0.0%) | 154.0K +6.6K (+4.5%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD0.85 +805.9% | 13 qtrs — |
| 77 | SG AMERICAS SECURITIES, LLC | 20.0K +20.0K (+100.0%) | 154.0K +154.0K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 78 | GRAHAM CAPITAL MANAGEMENT, L.P. | 19.3K +19.3K (+100.0%) | 148.4K +148.4K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.004 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 79 | TWO SIGMA ADVISERS, LP | 18.9K -142.7K (-88.3%) | 145.5K -1.0M (-87.8%) | 0.02% -0.185 pp | 0.00% -0.002 pp | USD3.08 +150.0% | 20 qtrs — |
| 80 | NEW YORK STATE COMMON RETIREMENT FUND | 18.8K +— (+0.0%) | 144.8K +6.2K (+4.5%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD4.00 +92.5% | 3 qtrs — |
| 81 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 18.2K +5.1K (+39.1%) | 139.9K +43.6K (+45.3%) | 0.02% +0.005 pp | 0.01% +0.003 pp | USD5.85 +31.6% | 5 qtrs — |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 17.5K -1.2K (-6.6%) | 134.7K -3.3K (-2.4%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD4.00 +92.5% | 3 qtrs — |
| 83 | ALLIANCEBERNSTEIN L.P. | 17.1K +— (+0.0%) | 131.8K +5.7K (+4.5%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD4.00 +92.5% | 3 qtrs — |
| 84 | SOWELL FINANCIAL SERVICES LLC | 17.0K +5.0K (+41.7%) | 130.9K +42.5K (+48.0%) | 0.02% +0.005 pp | 0.00% +0.001 pp | USD4.51 +70.7% | 4 qtrs — |
| 85 | SHELTON WEALTH MANAGEMENT, LLC | 15.6K +1.9K (+13.8%) | 120.4K +19.1K (+18.9%) | 0.02% +0.001 pp | 0.05% +0.006 pp | USD7.41 +3.9% | 2 qtrs — |
| 86 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 15.5K +— (+0.0%) | 119.6K +5.1K (+4.5%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD4.71 +63.5% | 3 qtrs — |
| 87 | CITIGROUP INC | 14.9K +10.9K (+276.3%) | 114.4K +85.3K (+293.2%) | 0.02% +0.013 pp | 0.00% +0.000 pp | USD6.74 +14.2% | 6 qtrs — |
| 88 | GSA CAPITAL PARTNERS LLP | 14.2K -387.2K (-96.5%) | 109.0K -2.8M (-96.3%) | 0.02% -0.499 pp | 0.01% -0.237 pp | USD4.69 +64.2% | 5 qtrs — |
| 89 | PROSHARE ADVISORS LLC | 13.8K +979.0 (+7.7%) | 106.0K +11.8K (+12.5%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD4.26 +80.8% | 3 qtrs — |
| 90 | AXQ CAPITAL, LP | 12.6K -14.5K (-53.4%) | 97.0K -102.3K (-51.3%) | 0.02% -0.020 pp | 0.02% -0.055 pp | USD7.37 +4.5% | 2 qtrs — |
| 91 | FOX RUN MANAGEMENT, L.L.C. | 11.2K +11.2K (+100.0%) | 86.4K +86.4K (+100.0%) | 0.01% +0.014 pp | 0.01% +0.013 pp | USD7.70 +0.0% | 1 qtrs NEW |
| 92 | WHITTIER TRUST CO OF NEVADA INC | 11.2K +— (+0.0%) | 74.8K -5.7K (-7.1%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD2.42 +218.2% | 22 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 86 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | F/M Emerald Life Sciences Innovation ETF LFSC | 2.10% | 1.57M | 0.54% |
| 2 | Tema Oncology ETF CANC | 1.11% | 1.58M | 0.75% |
| 3 | iShares Genomics Immunology and Healthcare ETF IDNA | 1.09% | 2.13M | 0.47% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.81% | 465.4K | 0.65% |
| 5 | ALPS Medical Breakthroughs ETF SBIO | 0.68% | 1.44M | 0.50% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.43% | 153.3K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.43% | 46.06M | 0.35% |
| 8 | iShares Micro-Cap ETF IWC | 0.24% | 3.57M | 0.60% |
| 9 | VictoryShares US Small Mid Cap Value Momentum ETF USVM | 0.19% | 3.35M | 0.29% |
| 10 | Vanguard U.S. Momentum Factor ETF VFMO | 0.13% | 2.26M | 0.13% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
13
Sells
13
Shares acquired
210.0K
Shares disposed
210.0K
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Chan Andrew C. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 16.02 | 480.6K | 30,000 | D | ↗ |
| 2026-01-28 | Thompson Peter A. | Director / 10% Owner | M-Exempt | A | Common Stock | 30,000 | 15.00 | 450.0K | 30,000 | D | ↗ |
| 2025-12-04 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,000,000 | 8.81 | 8.81M | 1,000,000 | D | ↗ |
| 2025-12-04 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 8.81 | 3.52M | 400,000 | D | ↗ |
| 2025-12-04 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 8.81 | 3.52M | 400,000 | D | ↗ |
| 2025-12-04 | Arcara Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 8.81 | 881.0K | 100,000 | D | ↗ |
| 2025-10-02 | Moore David Scott | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 7.04 | 211.2K | 30,000 | D | ↗ |
| 2025-06-27 | Thompson Peter A. | Director / 10% Owner | X-InTheMoney | A | Common Stock | 1,397,684 | 3.50 | 4.89M | 8,341,338 | I | ↗ |
| 2025-06-27 | ORBIMED ADVISORS LLC | Director / 10% Owner | X-InTheMoney | A | Common Stock | 1,397,684 | 3.50 | 4.89M | 8,341,338 | I | ↗ |
| 2025-06-12 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.24 | 63.6K | 15,000 | D | ↗ |
| 2025-06-12 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.24 | 63.6K | 15,000 | D | ↗ |
| 2025-06-12 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.24 | 63.6K | 15,000 | D | ↗ |
| 2025-06-12 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.24 | 63.6K | 15,000 | D | ↗ |
| 2025-06-04 | Jones William Benton | Officer | M-Exempt | A | Common Stock | 19,357 | 3.50 | 67.7K | 173,130 | D | ↗ |
| 2025-05-07 | MILLER RICHARD A MD | Director / Officer | M-Exempt | D | Warrant (Right to Buy) | 559,073 | 3.50 | 1.96M | 0 | D | ↗ |
| 2025-04-08 | van den Broek Richard | Director | — | — | Common Stock | 0 | 0.00 | — | 160,000 | I | ↗ |
| 2024-12-20 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 4.99 | 3.74M | 750,000 | D | ↗ |
| 2024-12-20 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 4.99 | 1.50M | 300,000 | D | ↗ |
| 2024-12-20 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 4.99 | 1.50M | 300,000 | D | ↗ |
| 2024-12-20 | Arcara Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 4.99 | 249.5K | 50,000 | D | ↗ |
| 2024-06-13 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.12 | 31.8K | 15,000 | — | ↗ |
| 2024-06-13 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.12 | 31.8K | 15,000 | — | ↗ |
| 2024-06-13 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.12 | 31.8K | 15,000 | — | ↗ |
| 2024-06-13 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.12 | 31.8K | 15,000 | — | ↗ |
| 2024-06-13 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.12 | 31.8K | 15,000 | — | ↗ |
| 2024-05-10 | MILLER RICHARD A MD | Director / Officer | G-Gift | D | Common Stock | 302,016 | 0.00 | — | 1,188,103 | — | ↗ |
| 2024-05-06 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Pre-Funded Warrants (right to buy) | 1,444,085 | 0.00 | 144.41 | 1,444,085 | — | ↗ |
| 2024-05-06 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Warrants (right to buy) | 1,397,684 | 3.50 | 4.89M | 1,397,684 | — | ↗ |
| 2024-05-06 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 577,634 | 1.73 | 1,000.0K | 577,634 | — | ↗ |
| 2024-05-06 | Jones William Benton | Officer | P-Purchase | A | Warrant (Right to Buy) | 19,357 | 3.50 | 67.7K | 19,357 | — | ↗ |
| 2024-02-28 | Arcara Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 2.30 | 920.0K | 400,000 | — | ↗ |
| 2024-02-02 | Arcara Jeffrey | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-06 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.64 | 24.6K | 15,000 | — | ↗ |
| 2023-12-06 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.64 | 24.6K | 15,000 | — | ↗ |
| 2023-12-06 | Mitchell Edith P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.64 | 24.6K | 15,000 | — | ↗ |
| 2023-12-06 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.64 | 820.0K | 500,000 | — | ↗ |
| 2023-12-06 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 1.64 | 328.0K | 200,000 | — | ↗ |
| 2023-12-06 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 1.64 | 328.0K | 200,000 | — | ↗ |
| 2023-12-06 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.64 | 24.6K | 15,000 | — | ↗ |
| 2023-12-06 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.64 | 24.6K | 15,000 | — | ↗ |
| 2023-12-06 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.64 | 24.6K | 15,000 | — | ↗ |
| 2023-06-15 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.49 | 37.4K | 15,000 | — | ↗ |
| 2023-06-15 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.49 | 37.4K | 15,000 | — | ↗ |
| 2023-06-15 | Mitchell Edith P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.49 | 37.4K | 15,000 | — | ↗ |
| 2023-06-15 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.49 | 37.4K | 15,000 | — | ↗ |
| 2023-06-15 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.49 | 37.4K | 15,000 | — | ↗ |
| 2023-06-15 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.49 | 37.4K | 15,000 | — | ↗ |
| 2023-05-15 | Grais Linda | Director | P-Purchase | A | Common Stock | 10,000 | 2.45 | 24.5K | 10,000 | — | ↗ |
| 2023-03-31 | MILLER RICHARD A MD | — | A-Award | A | Stock Option (Right to Buy) | 800,000 | 0.91 | 728.0K | 800,000 | — | ↗ |
| 2022-12-20 | Jones William Benton | Officer | P-Purchase | A | Common Stock | 20,000 | 0.79 | 15.8K | 133,773 | — | ↗ |
| 2022-12-14 | MILLER RICHARD A MD | Officer | P-Purchase | A | Common Stock | 10,000 | 0.78 | 7.8K | 1,490,119 | — | ↗ |
| 2022-12-14 | LEA LEIV | Officer | P-Purchase | A | Common Stock | 4,000 | 0.84 | 3.4K | 133,238 | — | ↗ |
| 2022-12-13 | MILLER RICHARD A MD | Officer | P-Purchase | A | Common Stock | 50,000 | 0.74 | 37.0K | 1,480,119 | — | ↗ |
| 2022-12-13 | LEA LEIV | Officer | P-Purchase | A | Common Stock | 30,000 | 0.74 | 22.3K | 129,238 | — | ↗ |
| 2022-09-28 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 0.76 | 19.1K | 1,394,405 | — | ↗ |
| 2022-09-20 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 2,700 | 0.82 | 2.2K | 1,364,405 | — | ↗ |
| 2022-08-11 | Thompson Peter A. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-08-11 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-08-11 | Mitchell Edith P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-08-11 | MILLER RICHARD A MD | Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 0.00 | — | 320,000 | — | ↗ |
| 2022-08-11 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 0.00 | — | 160,000 | — | ↗ |
| 2022-08-11 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 0.00 | — | 160,000 | — | ↗ |
| 2022-08-11 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-08-11 | Gould Terry P | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-08-11 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.97 | 14.5K | 15,000 | — | ↗ |
| 2022-08-11 | ADAMS STREET PARTNERS LLC | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-24 | MILLER RICHARD A MD | Officer | P-Purchase | A | Common Stock | 5,000 | 1.00 | 5.0K | 1,349,405 | — | ↗ |
| 2022-06-15 | Thompson Peter A. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-15 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-15 | Mitchell Edith P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-15 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-15 | Gould Terry P | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-15 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.99 | 14.8K | 15,000 | — | ↗ |
| 2022-06-02 | MILLER RICHARD A MD | Officer | P-Purchase | A | Common Stock | 890 | 1.01 | 898.90 | 1,339,405 | — | ↗ |
| 2022-03-31 | MILLER RICHARD A MD | Officer | P-Purchase | A | Common Stock | 15,000 | 1.64 | 24.5K | 1,333,515 | — | ↗ |
| 2022-03-16 | LEA LEIV | Officer | P-Purchase | A | Common Stock | 13,878 | 1.65 | 22.9K | 99,238 | — | ↗ |
| 2022-03-15 | MILLER RICHARD A MD | Officer | P-Purchase | A | Common Stock | 5,000 | 1.59 | 8.0K | 1,318,515 | — | ↗ |
| 2021-10-01 | EcoR1 Capital, LLC | 10% Owner | S-Sale | D | Common Stock | 2,000,000 | 4.96 | 9.93M | 81,077 | — | ↗ |
| 2021-09-30 | EcoR1 Capital, LLC | 10% Owner | S-Sale | D | Common Stock | 3,000,000 | 5.04 | 15.13M | 2,081,077 | — | ↗ |
| 2021-09-22 | EcoR1 Capital, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 5,081,077 | — | ↗ |
| 2021-09-20 | Thompson Peter A. | Director / 10% Owner | S-Sale | D | Common Stock, $0.0001 par value | 1,109,644 | 6.09 | 6.76M | 6,943,654 | — | ↗ |
| 2021-09-20 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock, $0.0001 par value | 1,109,644 | 6.09 | 6.76M | 6,943,654 | — | ↗ |
| 2021-09-09 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.60 | 39.0K | 15,000 | — | ↗ |
| 2021-09-09 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.60 | 39.0K | 15,000 | — | ↗ |
| 2021-09-09 | Mitchell Edith P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.60 | 39.0K | 15,000 | — | ↗ |
| 2021-09-09 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 2.60 | 832.0K | 320,000 | — | ↗ |
| 2021-09-09 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 2.60 | 416.0K | 160,000 | — | ↗ |
| 2021-09-09 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 2.60 | 416.0K | 160,000 | — | ↗ |
| 2021-09-09 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.60 | 39.0K | 15,000 | — | ↗ |
| 2021-09-09 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.60 | 39.0K | 15,000 | — | ↗ |
| 2021-09-09 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.60 | 39.0K | 15,000 | — | ↗ |
| 2021-09-09 | ADAMS STREET PARTNERS LLC | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.60 | 39.0K | 15,000 | — | ↗ |
| 2021-08-20 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.93 | 19.3K | 1,288,515 | — | ↗ |
| 2021-06-15 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.74 | 41.1K | 15,000 | — | ↗ |
| 2021-06-15 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.74 | 41.1K | 15,000 | — | ↗ |
| 2021-06-15 | Mitchell Edith P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.74 | 41.1K | 15,000 | — | ↗ |
| 2021-06-15 | Grais Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.74 | 41.1K | 15,000 | — | ↗ |
| 2021-06-15 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.74 | 41.1K | 15,000 | — | ↗ |
| 2021-06-15 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.74 | 41.1K | 15,000 | — | ↗ |
| 2021-06-15 | ADAMS STREET PARTNERS LLC | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.74 | 41.1K | 15,000 | — | ↗ |
| 2021-05-04 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 35,714 | 2.80 | 100.0K | 35,714 | — | ↗ |
| 2021-02-17 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 1,285,714 | 3.50 | 4.50M | 8,053,298 | — | ↗ |
| 2021-02-17 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 1,285,714 | 3.50 | 4.50M | 8,053,298 | — | ↗ |
| 2021-02-17 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 3.50 | 350.0K | 1,278,515 | — | ↗ |
| 2020-12-16 | Mobasher Mehrdad | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 4.01 | 340.9K | 85,000 | — | ↗ |
| 2020-12-16 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 4.01 | 1.28M | 320,000 | — | ↗ |
| 2020-12-16 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 4.01 | 641.6K | 160,000 | — | ↗ |
| 2020-12-16 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 4.01 | 641.6K | 160,000 | — | ↗ |
| 2020-09-10 | Mitchell Edith P. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.95 | 118.5K | 30,000 | — | ↗ |
| 2020-07-08 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 741,440 | 5.37 | 3.99M | 1,389,498 | — | ↗ |
| 2020-07-07 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 796,622 | 5.25 | 4.18M | 2,130,938 | — | ↗ |
| 2020-06-09 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.27 | 49.1K | 15,000 | — | ↗ |
| 2020-06-09 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.27 | 49.1K | 15,000 | — | ↗ |
| 2020-06-09 | Krognes Steve E. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.27 | 49.1K | 15,000 | — | ↗ |
| 2020-06-09 | Grais Linda S | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.27 | 49.1K | 15,000 | — | ↗ |
| 2020-06-09 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.27 | 49.1K | 15,000 | — | ↗ |
| 2020-06-09 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.27 | 49.1K | 15,000 | — | ↗ |
| 2020-06-09 | ADAMS STREET PARTNERS LLC | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.27 | 49.1K | 15,000 | — | ↗ |
| 2020-04-30 | Novo Holdings A/S | 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 2,927,560 | — | ↗ |
| 2020-03-19 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2020-03-19 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2020-03-19 | Krognes Steve E. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2020-03-19 | Grais Linda S | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2020-03-19 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2020-03-19 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2020-03-19 | ADAMS STREET PARTNERS LLC | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2019-12-12 | Verner Erik J. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 3.54 | 177.0K | 50,000 | — | ↗ |
| 2019-12-12 | Mobasher Mehrdad | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 3.54 | 177.0K | 50,000 | — | ↗ |
| 2019-12-12 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 3.54 | 1.13M | 320,000 | — | ↗ |
| 2019-12-12 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 3.54 | 566.4K | 160,000 | — | ↗ |
| 2019-12-12 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 3.54 | 566.4K | 160,000 | — | ↗ |
| 2019-12-12 | Hunt Daniel W. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 3.54 | 265.5K | 75,000 | — | ↗ |
| 2019-12-12 | Buggy Joseph J | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.54 | 141.6K | 40,000 | — | ↗ |
| 2019-11-13 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 14,736 | 3.00 | 44.2K | 1,178,515 | — | ↗ |
| 2019-11-12 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock | 272 | 2.90 | 788.80 | 1,163,779 | — | ↗ |
| 2019-08-07 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 2,500 | 3.54 | 8.9K | 1,163,507 | — | ↗ |
| 2019-08-06 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 142,656 | 3.51 | 500.7K | 6,767,584 | — | ↗ |
| 2019-08-06 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 142,656 | 3.51 | 500.7K | 6,767,584 | — | ↗ |
| 2019-08-06 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 5,000 | 3.58 | 17.9K | 1,161,007 | — | ↗ |
| 2019-07-25 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 1,400,000 | 4.00 | 5.60M | 2,927,560 | — | ↗ |
| 2019-07-24 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 53,240 | 5.01 | 266.7K | 4,327,560 | — | ↗ |
| 2019-07-23 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 39,716 | 5.32 | 211.1K | 4,380,800 | — | ↗ |
| 2019-07-01 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 59,243 | 3.91 | 231.6K | 6,624,928 | — | ↗ |
| 2019-07-01 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 59,243 | 3.91 | 231.6K | 6,624,928 | — | ↗ |
| 2019-06-28 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 565,178 | 3.72 | 2.10M | 6,565,685 | — | ↗ |
| 2019-06-28 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 565,178 | 3.72 | 2.10M | 6,565,685 | — | ↗ |
| 2019-06-27 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 32,923 | 3.34 | 110.0K | 6,000,507 | — | ↗ |
| 2019-06-27 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 32,923 | 3.34 | 110.0K | 6,000,507 | — | ↗ |
| 2019-06-20 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.61 | 54.2K | 15,000 | — | ↗ |
| 2019-06-20 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.61 | 54.2K | 15,000 | — | ↗ |
| 2019-06-20 | Krognes Steve E. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.61 | 54.2K | 15,000 | — | ↗ |
| 2019-06-20 | Grais Linda S | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.61 | 54.2K | 15,000 | — | ↗ |
| 2019-06-20 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.61 | 54.2K | 15,000 | — | ↗ |
| 2019-06-20 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.61 | 54.2K | 15,000 | — | ↗ |
| 2019-06-20 | ADAMS STREET PARTNERS LLC | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.61 | 54.2K | 15,000 | — | ↗ |
| 2019-06-14 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 11,657 | 3.40 | 39.7K | 1,156,007 | — | ↗ |
| 2019-06-13 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 343 | 3.52 | 1.2K | 1,144,350 | — | ↗ |
| 2019-06-11 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 6,000 | 3.67 | 22.0K | 1,144,007 | — | ↗ |
| 2019-06-07 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 9,212 | 3.37 | 31.0K | 1,138,007 | — | ↗ |
| 2019-06-07 | LEA LEIV | Officer | P-Purchase | A | Common Stock, $0.0001 par value | 10,000 | 3.38 | 33.8K | 50,200 | — | ↗ |
| 2019-06-06 | LEA LEIV | Officer | P-Purchase | A | Common Stock, $0.0001 par value | 15,500 | 3.56 | 55.2K | 40,200 | — | ↗ |
| 2019-01-28 | Mobasher Mehrdad | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 3.88 | 814.8K | 210,000 | — | ↗ |
| 2019-01-28 | Grais Linda S | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.88 | 116.4K | 30,000 | — | ↗ |
| 2018-12-27 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 20,000 | 3.29 | 65.9K | 1,128,795 | — | ↗ |
| 2018-12-21 | LEA LEIV | Officer | P-Purchase | A | Common Stock, $0.0001 par value | 24,700 | 4.15 | 102.4K | 24,700 | — | ↗ |
| 2018-12-20 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 5,000 | 4.39 | 22.0K | 1,108,795 | — | ↗ |
| 2018-12-12 | Verner Erik J. | Officer | A-Award | D | Stock Option (Right to Buy) | 50,000 | 5.94 | 297.0K | 50,000 | — | ↗ |
| 2018-12-12 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 5.94 | 1.49M | 250,000 | — | ↗ |
| 2018-12-12 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 5.94 | 594.0K | 100,000 | — | ↗ |
| 2018-12-12 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 5.94 | 594.0K | 100,000 | — | ↗ |
| 2018-12-12 | Hunt Daniel W. | Officer | A-Award | D | Stock Option (Right to Buy) | 50,000 | 5.94 | 297.0K | 50,000 | — | ↗ |
| 2018-12-12 | Buggy Joseph J | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 5.94 | 594.0K | 100,000 | — | ↗ |
| 2018-12-11 | MILLER RICHARD A MD | Director / Officer | G-Gift | D | Common Stock, $0.0001 par value | 10,000 | 0.00 | — | 1,108,795 | — | ↗ |
| 2018-12-06 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 5,000 | 5.99 | 29.9K | 1,118,795 | — | ↗ |
| 2018-12-04 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 1,502 | 5.95 | 8.9K | 1,113,795 | — | ↗ |
| 2018-06-21 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.50 | 187.5K | 15,000 | — | ↗ |
| 2018-06-21 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.50 | 187.5K | 15,000 | — | ↗ |
| 2018-06-21 | Krognes Steve E. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.50 | 187.5K | 15,000 | — | ↗ |
| 2018-06-21 | Gould Terry P | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.50 | 187.5K | 15,000 | — | ↗ |
| 2018-06-21 | CLARK IAN T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.50 | 187.5K | 15,000 | — | ↗ |
| 2018-06-21 | ADAMS STREET PARTNERS LLC | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.50 | 187.5K | 15,000 | — | ↗ |
| 2018-03-12 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 588,235 | 8.50 | 5.00M | 5,967,584 | — | ↗ |
| 2018-03-12 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 588,235 | 8.50 | 5.00M | 5,967,584 | — | ↗ |
| 2018-03-12 | Novo Holdings A/S | 10% Owner | P-Purchase | A | COMMON STOCK | 1,176,470 | 8.50 | 10.00M | 4,420,516 | — | ↗ |
| 2018-03-12 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 100,000 | 8.50 | 850.0K | 1,112,293 | — | ↗ |
| 2018-03-12 | Gould Terry P | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 69,864 | 8.50 | 593.8K | 69,864 | — | ↗ |
| 2018-03-12 | ADAMS STREET PARTNERS LLC | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 69,864 | 8.50 | 593.8K | 69,864 | — | ↗ |
| 2018-01-19 | Buggy Joseph J | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 9.94 | 994.0K | 100,000 | — | ↗ |
| 2017-12-13 | Verner Erik J. | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 10.60 | 265.0K | 25,000 | — | ↗ |
| 2017-12-13 | MILLER RICHARD A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 10.60 | 1.33M | 125,000 | — | ↗ |
| 2017-12-13 | LEA LEIV | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 10.60 | 424.0K | 40,000 | — | ↗ |
| 2017-12-13 | Jones William Benton | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 10.60 | 424.0K | 40,000 | — | ↗ |
| 2017-12-13 | Hunt Daniel W. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 10,000 | 10.79 | 107.9K | 1,012,293 | — | ↗ |
| 2017-06-23 | Novo Holdings A/S | 10% Owner | P-Purchase | A | COMMON STOCK | 20,000 | 10.95 | 219.0K | 3,244,046 | — | ↗ |
| 2017-06-13 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 2,500 | 10.14 | 25.4K | 1,002,293 | — | ↗ |
| 2017-06-12 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 11,216 | 9.82 | 110.2K | 997,293 | — | ↗ |
| 2017-06-09 | MILLER RICHARD A MD | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 3,784 | 9.89 | 37.4K | 986,077 | — | ↗ |
| 2017-06-08 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.70 | 145.5K | 15,000 | — | ↗ |
| 2017-06-08 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.70 | 145.5K | 15,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
84.09M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Richard A. Miller, M.D. President and Chief Executive Officer | 36.6K | — | — | 6.99M | — | 6.0K | 7.03M | 99.39% | ↗ |
| 2 | 2025 | Leiv Lea Chief Financial Officer | 405.9K | — | — | 2.80M | — | 6.0K | 3.21M | 87.16% | ↗ |
| 3 | 2025 | William B. Jones, Ph.D. Senior Vice President, Pharmaceutical Development | 360.1K | — | — | 2.80M | — | 6.0K | 3.16M | 88.42% | ↗ |
| 4 | 2024 | Richard A. Miller, M.D. President and Chief Executive Officer | 32.7K | — | — | 3.03M | — | 6.0K | 3.07M | 98.74% | ↗ |
| 5 | 2024 | Leiv Lea Chief Financial Officer | 394.7K | — | — | 1.21M | — | 6.0K | 1.61M | 75.18% | ↗ |
| 6 | 2024 | William B. Jones, Ph.D. Senior Vice President, Pharmaceutical Development | 350.1K | — | — | 1.21M | — | 6.0K | 1.57M | 77.32% | ↗ |
| 7 | 2023 | Richard A. Miller, M.D. President and Chief Executive Officer | 110.3K | — | — | 1.21M | — | 6.0K | 1.32M | 91.20% | ↗ |
| 8 | 2023 | Leiv Lea Chief Financial Officer | 394.2K | — | — | 260.6K | — | 6.0K | 660.8K | 39.43% | ↗ |
| 9 | 2023 | William B. Jones, Ph.D. Senior Vice President, Pharmaceutical Development | 349.7K | — | — | 260.6K | — | 6.0K | 616.3K | 42.28% | ↗ |
| 10 | 2022 | Richard A. Miller, M.D. President and Chief Executive Officer | 300.0K | — | — | 218.2K | — | 6.0K | 524.2K | 41.63% | ↗ |
| 11 | 2022 | Leiv Lea Chief Financial Officer | 382.7K | — | — | 109.1K | — | 6.0K | 497.9K | 21.92% | ↗ |
| 12 | 2022 | William B. Jones, Ph.D. Senior Vice President, Pharmaceutical Development | 340.4K | — | — | 109.1K | — | 6.0K | 455.5K | 23.95% | ↗ |
| 13 | 2021 | Richard A. Miller, M.D. President and Chief Executive Officer | 300.0K | — | — | 602.1K | — | 3.0K | 905.1K | 66.52% | ↗ |
| 14 | 2021 | Leiv Lea Chief Financial Officer | 371.6K | — | — | 301.0K | 74.4K | 3.0K | 750.0K | 40.14% | ↗ |
| 15 | 2021 | William B. Jones, Ph.D. Senior Vice President, Pharmaceutical Development | 331.4K | — | — | 301.0K | 66.0K | 3.0K | 701.4K | 42.92% | ↗ |
| 16 | 2020 | Richard A. Miller, M.D. President and Chief Executive Officer | 300.0K | — | — | 885.3K | — | 3.0K | 1.19M | 74.50% | ↗ |
| 17 | 2020 | Leiv Lea Chief Financial Officer | 360.2K | — | — | 442.6K | 36.1K | 3.0K | 841.9K | 52.58% | ↗ |
| 18 | 2020 | William B. Jones, Ph.D. Senior Vice President, Pharmaceutical Development | 318.1K | — | — | 442.6K | 31.8K | 3.0K | 795.6K | 55.64% | ↗ |
| 19 | 2019 | Mehrdad Mobasaher, M.D. Vice President and Chief Medical Officer | 406.7K | 245.0K | — | 702.4K | — | 3.0K | 1.36M | 51.76% | ↗ |
| 20 | 2019 | Richard A. Miller, M.D. President and Chief Executive Officer | 300.0K | — | — | 795.0K | — | 3.0K | 1.10M | 72.41% | ↗ |
| 21 | 2019 | Leiv Lea Chief Financial Officer | 349.3K | — | — | 397.5K | — | 3.0K | 749.8K | 53.01% | ↗ |
| 22 | 2019 | William B. Jones, Ph.D. Senior Vice President, Pharmaceutical Development | 308.6K | — | — | 397.5K | — | 3.0K | 709.2K | 56.05% | ↗ |
| 23 | 2018 | Richard A. Miller, M.D. President and Chief Executive Officer | 300.0K | — | — | 1.06M | — | 3.0K | 1.36M | 77.71% | ↗ |
| 24 | 2018 | Joseph J. Buggy, Ph.D. Executive Vice President, Discovery Research | 143.6K | — | — | 1.14M | — | — | 1.28M | 88.79% | ↗ |
| 25 | 2018 | Leiv Lea Chief Financial Officer | 319.3K | — | — | 422.5K | — | 3.0K | 744.9K | 56.73% | ↗ |
| 26 | 2017 | Daniel W. Hunt, J.D. Senior Vice President and Chief Business Officer | 36.1K | — | — | 1.52M | — | — | 1.55M | 97.68% | ↗ |
| 27 | 2017 | Richard A. Miller, M.D. President and Chief Executive Officer | 301.8K | — | — | 948.8K | — | 2.0K | 1.25M | 75.74% | ↗ |
| 28 | 2017 | Leiv Lea Chief Financial Officer | 291.4K | — | — | 303.6K | — | 2.0K | 597.0K | 50.85% | ↗ |
| 29 | 2016 | Richard A. Miller, M.D. President and Chief Executive Officer | 291.8K | — | — | 7.25M | — | — | 7.54M | 96.13% | ↗ |
| 30 | 2016 | Jason Coloma, Ph.D. Senior Vice President and Chief Business Officer | 214.0K | — | — | 1.89M | — | 198.8K | 2.30M | 82.08% | ↗ |
| 31 | 2016 | Leiv Lea Chief Financial Officer | 264.9K | — | — | 938.5K | — | — | 1.20M | 77.99% | ↗ |
| 32 | 2015 | Richard A. Miller, M.D. President and Chief Executive Officer | 252.8K | — | — | 500.1K | — | — | 752.9K | 66.43% | ↗ |
| 33 | 2015 | Leiv Lea Chief Financial Officer | 225.9K | — | — | 62.5K | — | — | 288.4K | 21.68% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Leiv Lea | Chief Financial Officer | 411.9K | male |
| William Benton Jones | Senior Vice President of Pharmaceutical Development | 366.1K | — |
| Peter A. Thompson FACP | Co-Founder & Independent Director | 47.0K | — |
| Richard A. Miller | Co-Founder, President, Chief Executive Officer & Chairman of the Board | 42.6K | — |
| Jeffrey S. Arcara | Senior Vice President & Chief Business Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRVS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
